1.The tests and correlation analysis of HBV-DNA and hepatic fibrosis indicators in chronic hepatitis B patients
International Journal of Laboratory Medicine 2014;(17):2311-2312
Objective To explore the correlation between serum HBV-DNA content and hepatic fibrosis indicators in hchronic epatitis B patients.Methods Serum HBV-DNA content was determined by using real-time fluorescence quantitative PCR and he-patic fibrosis indicators including hyaluronic acid,laminin,procollagen Ⅲ,and collagen Ⅳ which were determined by using chemilu-minescence.Results The logarithm value of serum HBV-DNA content of the 110 hepatitis B patients was 5.32±1.37.Serum hyal-uronic acid concentration was (197.81 ±85.37)mg/mL;procollagen Ⅲ concentration was (142.66 ±30.28)μg/mL.Collagen Ⅳconcentration was (90.34 ±20.53)μg/mL.Laminin was (143.96 ±31.79 )μg/mL.All these indicators were significantly higher than the control group (P <0.01).But there were no significant linear correlation between serum HBV-DNA content and the four hepatic fibrosis indicators(P >0.05).Conclusion The hepatic fibrosis indicators increased significantly in hepatitis B patients but there were no significant correlations between serum HBV-DNA content and the hepatic fibrosis indicators.
2.Expression of PHH3 and cyclinD1 and their clinical significance in breast invasive ductal carcinoma
Lili HAN ; Xiangyun WANG ; Jiming ZHAO
Chinese Journal of Primary Medicine and Pharmacy 2016;(4):492-496
Objective To investigate the association between expression of PHH3 and CyclinD1 and their significance in breast invasive ductal carcinoma.Methods Immunostoemical MaxVision staining was used to detect the expression of PHH3 and CyclinD1 in 89 samples of breast invasive ductal carcinoma and 30 samples of normal breast tissues.The correlation was then analyzed between the expression of PHH3 and CyclinD1 and the clinical path-ological parameters as well as prognosis.Results The positive rate of PHH3 in breast invasive ductal carcinoma tis-sues(68 /89,76.4%)was significantly higher than that in normal breast tissues(2 /30,6.7%)(χ2 =45.051,P <0.05).The expression level of PHH3 was significantly correlated with tumor histological degree(χ2 =10.540,P <0.05),anillary lymph node metastasis(χ2 =6.852,P <0.05)and TNMstage(χ2 =5.634,P <0.05),but it was not related to the age(χ2 =1.054,P >0.05 )and the tumor diameter(χ2 =0.014,P >0.05 ).The positive rate of CyclinD1 in breast invasive ductal carcinoma tissues(62 /89,69.7%)was significantly higher than that in normal breast tissues(3 /10,10.0%)(χ2 =32.223,P <0.05).The expression level of CyclinD1 was significantly correlated with tumor histological degree(χ2 =13.328,P <0.05),anillary lymph node metastasis(χ2 =5.041,P <0.05)and TNMstage(χ2 =4.419,P <0.05),but it was not related to the age(χ2 =0.500,P >0.05)and the tumor diameter (χ2 =1.836,P >0.05).The expression of PHH3 was directly correlated to the CyclinD1 (r =0.497,P <0.05). Kaplan-Meier analysis showed that the expression of PHH3 was negatively correlated with prognosis.Log-Rank test indicated that there was significant difference(χ2 =10.468,P <0.05),CyclinD1 was negatively correlated with prog-nosis.Log-Rank test indicated that there was significant difference (χ2 =7.906,P <0.05 ).Conclusion High expression of PHH3 and CyclinD1 may be correlated with evolution and metastasis of breast invasive ductal carcino-ma.Combined analysis of PHH3 and CyclinD1 may provide a theoretical basis for prognostic information and treatment of patients with breast cancer.
3.Analysis on published papers from 2003 to 2012 by Disease control agencies of Chongqing
Jiming KANG ; Wei LIANG ; Yu LIU ; Zhunhui HAN
Chinese Journal of Medical Science Research Management 2015;28(4):342-345
The author carried on bibliometrics statistical analysis of published papers during 2003-2012 by Disease control agencies of Chongqing and put forward some suggestions based on the results of the analysis.The results showed that in 10 years,the number of published papers for a total of 1154 with an average annual growth rate of 10.41%,of which 467 core journals,journal article 687.the difference between the municipal,district and county larger.The quantity and quality of published papers showed an upward trend,but there is still development space and the quality of the paper should be improved.
4.On the Teaching Production of China Medical University in Yan’an Period and Its Enlightenment
Huiqi HUANG ; Yushan HAN ; Jiming HAN
Chinese Medical Ethics 2022;35(8):886-893
During the Yan’an period, under the instructions of the CPC Central Committee and the Central Military Commission, the former Eighth Route Army Health School was expanded into China Medical University. As the first medical university founded by the Communist Party of China, this is a great practice of higher medical education in the new revolution. The school adhered to the policy of educating people with both ability and political integrity, the "saving the dying and healing the wounded, implementing revolutionary humanitarianism" has become the ideological guide and goal of the majority of revolutionary medical workers. The school provided a good teaching environment by strengthening teachers, enriching infrastructure and teaching equipment. Teachers and students have overcome difficulties and made great achievements in teaching and learning. At the same time, through the mass production movement and rectification movement, the development of the school was promoted from two aspects of material production and ideological construction. The practice of China Medical University in education policy, teaching curriculum and teaching content has certain enlightenment for today’s medical education.
5.The experience on the construction of the cluster prevention and control system for COVID-19 infection in designated hospitals during the period of "Category B infectious disease treated as Category A"
Wanjie YANG ; Xianduo LIU ; Ximo WANG ; Weiguo XU ; Lei ZHANG ; Qiang FU ; Jiming YANG ; Jing QIAN ; Fuyu ZHANG ; Li TIAN ; Wenlong ZHANG ; Yu ZHANG ; Zheng CHEN ; Shifeng SHAO ; Xiang WANG ; Li GENG ; Yi REN ; Ying WANG ; Lixia SHI ; Zhen WAN ; Yi XIE ; Yuanyuan LIU ; Weili YU ; Jing HAN ; Li LIU ; Huan ZHU ; Zijiang YU ; Hongyang LIU ; Shimei WANG
Chinese Critical Care Medicine 2024;36(2):195-201
The COVID-19 epidemic has spread to the whole world for three years and has had a serious impact on human life, health and economic activities. China's epidemic prevention and control has gone through the following stages: emergency unconventional stage, emergency normalization stage, and the transitional stage from the emergency normalization to the "Category B infectious disease treated as Category B" normalization, and achieved a major and decisive victory. The designated hospitals for prevention and control of COVID-19 epidemic in Tianjin has successfully completed its tasks in all stages of epidemic prevention and control, and has accumulated valuable experience. This article summarizes the experience of constructing a hospital infection prevention and control system during the "Category B infectious disease treated as Category A" period in designated hospital. The experience is summarized as the "Cluster" hospital infection prevention and control system, namely "three rings" outside, middle and inside, "three districts" of green, orange and red, "three things" before, during and after the event, "two-day pre-purification" and "two-director system", and "one zone" management. In emergency situations, we adopt a simplified version of the cluster hospital infection prevention and control system. In emergency situations, a simplified version of the "Cluster" hospital infection prevention and control system can be adopted. This system has the following characteristics: firstly, the system emphasizes the characteristics of "cluster" and the overall management of key measures to avoid any shortcomings. The second, it emphasizes the transformation of infection control concepts to maximize the safety of medical services through infection control. The third, it emphasizes the optimization of the process. The prevention and control measures should be comprehensive and focused, while also preventing excessive use. The measures emphasize the use of the least resources to achieve the best infection control effect. The fourth, it emphasizes the quality control work of infection control, pays attention to the importance of the process, and advocates the concept of "system slimming, process fattening". Fifthly, it emphasizes that the future development depends on artificial intelligence, in order to improve the quality and efficiency of prevention and control to the greatest extent. Sixth, hospitals need to strengthen continuous training and retraining. We utilize diverse training methods, including artificial intelligence, to ensure that infection control policies and procedures are simple. We have established an evaluation and feedback mechanism to ensure that medical personnel are in an emergency state at all times.
6. Clinical effect and safety of pegylated interferon-α-2b injection (Y shape, 40 kD) in treatment of HBeAg-positive chronic hepatitis B patients
Fengqin HOU ; Yalin YIN ; Lingying ZENG ; Jia SHANG ; Guozhong GONG ; Chen PAN ; Mingxiang ZHANG ; Chibiao YIN ; Qing XIE ; Yanzhong PENG ; Shijun CHEN ; Qing MAO ; Yongping CHEN ; Qianguo MAO ; Dazhi ZHANG ; Tao HAN ; Maorong WANG ; Wei ZHAO ; Jiajun LIU ; Ying HAN ; Longfeng ZHAO ; Guanghan LUO ; Jiming ZHANG ; Jie PENG ; Deming TAN ; Zhiwei LI ; Hong TANG ; Hao WANG ; Yuexin ZHANG ; Jun LI ; Lunli ZHANG ; Liang CHEN ; Jidong JIA ; Chengwei CHEN ; Zhen ZHEN ; Baosen LI ; Junqi NIU ; Qinghua MENG ; Hong YUAN ; Yongtao SUN ; Shuchen LI ; Jifang SHENG ; Jun CHENG ; Li SUN ; Guiqiang WANG
Chinese Journal of Hepatology 2017;25(8):589-596
Objective:
To investigate the clinical effect and safety of long-acting pegylated interferon-α-2b (Peg-IFN-α-2b) (Y shape, 40 kD) injection (180 μg/week) in the treatment of HBeAg-positive chronic hepatitis B (CHB) patients, with standard-dose Peg-IFN-α-2a as positive control.
Methods:
This study was a multicenter, randomized, open-label, and positive-controlled phase III clinical trial. Eligible HBeAg-positive CHB patients were screened out and randomized to Peg-IFN-α-2b (Y shape, 40 kD) trial group and Peg-IFN-α-2a control group at a ratio of 2:1. The course of treatment was 48 weeks and the patients were followed up for 24 weeks after drug withdrawal. Plasma samples were collected at screening, baseline, and 12, 24, 36, 48, 60, and 72 weeks for centralized detection. COBAS® Ampliprep/COBAS® TaqMan® HBV Test was used to measure HBV DNA level by quantitative real-time PCR. Electrochemiluminescence immunoassay with Elecsys kit was used to measure HBV markers (HBsAg, anti-HBs, HBeAg, anti-HBe). Adverse events were recorded in detail. The primary outcome measure was HBeAg seroconversion rate after the 24-week follow-up, and non-inferiority was also tested. The difference in HBeAg seroconversion rate after treatment between the trial group and the control group and two-sided confidence interval (